Clinical Trials Logo

Filter by:
NCT ID: NCT04532840 Active, not recruiting - Hypertrophic Scars Clinical Trials

Effect of Cryotherpy on Hypertrophic Scar

Start date: April 15, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

Purpose of the study: The purpose of the study is to evaluate the therapeutic effect of cryotherpy in treating hypertrophic scar. It will be hypothesized that: Cryotherapy may not have an effect on hypertrophic scar.

NCT ID: NCT04531163 Active, not recruiting - Clinical trials for Diabetes Mellitus, Type 2

Possible Ameliorating Effect of N- Acetylcysteine (NAC) on Type-II Diabetes Induced Nephropathy

(NAC)
Start date: October 1, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

The study is focused on the possible improving effect of N-acetylcysteine on nephropathy of type-2 diabetic patients. Study design: Prospective clinical based study. The aim of this work is to study the effect of N-acetylcysteine (NAC) on proteinuria and on the serum level of lipoprotein a (LPa) in diabetes induced nephropathy in type-2 diabetic patients.

NCT ID: NCT04530409 Active, not recruiting - Covid19 Clinical Trials

Timing of Corticosteroids in COVID-19, II. Post COVID-19 Follow-up

Start date: March 20, 2021
Phase: Phase 4
Study type: Interventional

Timing of of corticosteroids administration is very important in COVID19 cases for the recovery and decrease the mortality.

NCT ID: NCT04525339 Active, not recruiting - Clinical trials for Coronary Artery Disease

Early Outcomes of Concomitant Transcatheter Aortic Valve Implantation and Off-pump Coronary Artery Bypass Grafting in Management of Severe Symptomatic Aortic Stenosis and Coronary Artery Disease

Start date: July 1, 2020
Phase:
Study type: Observational

Study Objectives/Specific Aims Overall Goal: To study the outcomes of patients undergoing TAVI, their subsequent results and complications. - Objective 1: Identify risk factors that are predictive of the need for TAVI and CABG - Objective3:Assess early 3 months outcomes and postoperative results Outcome Measure: 1. All-cause mortality within 3 months. Secondary Outcome Measures: 1. Stroke 2. Myocardial infarction 3. Bleeding 4. Hospital stay 5. Acute kidney injury 6. Number of patients with conduction disturbance and pacemaker implantation 7. Gradient on implanted valve 8. Degree of transvalvular leakage 9. 6 weeks follow-up 10. 3 months Echo

NCT ID: NCT04477083 Active, not recruiting - Covid19 Clinical Trials

Development and Validation of "Ready-to-Use" Inhalable Forms of Hydroxychloroquine for Treatment of COVID-19

Start date: July 15, 2020
Phase: N/A
Study type: Interventional

In this project, we aimed at developing new "Ready-to-Use" inhalable forms of HCQ that can be used directly through nebulization or using dry powder inhalers (DPIs). These inhaled forms would allow a simple and direct delivery of the drug (HCQ) specifically towards the throat and the lung which are the main sites for the COVID-19 viral infection. Hence, the drug can be available at higher concentrations in the throat and lungs as compared with the currently used treatment protocols, while minimizing the drug systemic concentrations and its presence in other body organs, and thus enhancing the drug efficacy with significantly limiting its side effects. Besides, using inhalable forms can be more convenient to patients suffering from gastrointestinal complications from the disease that can limit the absorption of oral forms. Moreover, the proposed inhalable forms are designed in such a way to hide the drug from the immune system (confer stealth characteristics) using FDA-approved excipients to minimize/avoid any immune response towards the drug as was noted towards it in its oral form that's used in the treatment protocol of COVID-19. In addition, the inhaled formulations will be designed to maintain the overall simplicity and scalability of the preparation which is critical during this urgent pandemic situation. The cost of the final formulation is also taken into consideration since the drug is intended for treatment of thousands or probably millions of patients around the world including countries with limited economic capabilities.

NCT ID: NCT04463342 Active, not recruiting - Occlusal Caries Clinical Trials

Evaluation of Clinical Performance for Recent Non Coated Glass Ionomer in Posterior Teeth

Start date: September 3, 2019
Phase: Phase 1
Study type: Interventional

In patients with occlusal caries in posterior teeth, does the use of recently introduced non coated glass ionomer provide better clinical performance compared to conventional glass ionomer with surface coating? -Primary objective: To evaluate clinical performance of different types of restorations (Ketac molar with coating and Ketac Universal Aplicap 3M without coating) in occlusal caries in posterior teeth.

NCT ID: NCT04462120 Active, not recruiting - Covid-19 Clinical Trials

IL-12RB and TNF-alpha Gene Polymorphism and Susceptibility and Progress of Covid-19 SARS-CoV-2: A Case Control Study

Start date: June 16, 2020
Phase:
Study type: Observational

A novel coronavirus was identified in late 2019 in Wuhan, China On 11 February, The International Committee on Taxonomy of Viruses (ICTV) announced that the official classification of the new coronavirus (2019-nCoV) is called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The World Health Organization (WHO) announced on the same day that the official name of the disease caused by the virus is Corona Virus Disease-19 (COVID-19). WHO has declared the infection a Pandemic on March 11, 2020. Based on previous studies on SARS in 2003 and SARS-MERS 2013 there was a genetic polymorphism associated with the susceptibility and severity of the disease. Interleukin-12 (IL-12) is a cytokine secreted by activated phagocytes and dendritic cells. It plays a pivotal role in promoting Th1-type immune responses and cell-mediated immunity. IL-12 triggers many biological functions: it stimulates the proliferation of activated T- and NK-cells, enhances T- and NK-cell-mediated cytolytic activity, and induces the production of IFN-γ by both T-and NK-cells. The interferon-γ production induced by IL-12 forms a major link between innate and adaptive immunity. A recent study revealed that interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in SARS patients. Also, TNF-α is a key mediator of the inflammatory response and is critical for host defense against a wide variety of pathogenic microbes. However, the over-expression of this cytokine may lead to badness in disease recovery. The dual role of TNF, acting as an agent of both innate immunity and inflammatory pathology, poses a considerable challenge for gene regulation.

NCT ID: NCT04446390 Active, not recruiting - Dental Caries Clinical Trials

Preventive Regimens With Herbal and Fluoride Toothpaste on Remineralization in High Caries Patients With Initial Lesions

Start date: January 1, 2021
Phase: N/A
Study type: Interventional

This study will be conducted to assess the effect of different preventive regimens using herbal toothpaste versus fluoride toothpaste on the management of remineralization and caries risk in high caries risk patients.

NCT ID: NCT04444310 Active, not recruiting - COVID-19 Clinical Trials

Antibody Responses in Contacts of COVID-19 Patients

Start date: June 15, 2020
Phase:
Study type: Observational [Patient Registry]

After several cases of pneumonia with an unfamiliar etiology were observed at the end of 2019, the National Health Commission of China released more details about the epidemic in early 2020. The pathogen was identified as a novel coronavirus and named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as it has a phylogenetic similarity to SARS-CoV. Since then, SARS-CoV-2 has spread rapidly and the resulting coronavirus disease 2019 (COVID-19) has been declared a public health emergency of international concern (PHEIC) by the World Health Organization (WHO). SARS-CoV-2 is highly contagious, and there has not yet been any vaccine or effective treatment that has received approval. So, the best solution for controlling the pandemic will be the simultaneous application of preventive methods, sensitive diagnostic approaches, and using current available drugs, while still developing novel treatments. Coronaviruses are enveloped, non-segmented, single positive-stranded RNA viruses with round or oval particles and a diameter of 50-200 nm. Coronavirus subfamily is divided into four genera: α, β, γ and δ according to serotype and genomic characteristics.

NCT ID: NCT04443998 Active, not recruiting - Clinical trials for Mandibular Fractures

Mandibular Fracture Reduction Using Bone Reduction Forceps

Start date: October 16, 2019
Phase: N/A
Study type: Interventional

Different methods have been used in reducing mandibular fractures. Bone reduction forceps provides precise reduction and stabilize mandibular fracture segments.